April 11, 2013 at 17:22 PM EDT
Regeneron's Flagship Drug Treats Blindness In Seniors
IBD's biotech group is one of the biggest groups in the database, housing nearly 240 stocks. Nine stocks in the group have Composite Ratings of 97 or higher. Regeneron Pharmaceuticals (REGN) is one of the top stocks in the group with a Composite Rating of 99, the highest possible. Mutual fund ownership in Regeneron has ramped up over the past year. That's not surprising, given the early success of its flagship drug Eylea. Eylea is used to treat
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here